Back to today’s briefing

Story perspectives

Glycomine Secures $115M for Promising Genetic Disorder Therapy

4/17/2025

27 6

Summary

Story summary

Glycomine, a San Carlos-based biotech company, has raised an impressive $115 million in Series C funding to propel its promising therapy, GLM101, into a Phase 2b trial. This crucial investment aims to tackle PMM2-CDG, a rare and life-threatening genetic disorder that currently lacks approved treatments, offering hope to those affected.

1 of 1

Story summary

Glycomine, a San Carlos-based biotech company, has raised an impressive $115 million in Series C funding to propel its promising therapy, GLM101, into a Phase 2b trial. This crucial investment aims to tackle PMM2-CDG, a rare and life-threatening genetic disorder that currently lacks approved treatments, offering hope to those affected.